NerPharMa srl (NMS Group)
Is this your company? Claim this profile
Drug Product
Analytical & Bioanalytical Services
Clinical Trial Supply & Logistics
Regulatory, Tech Transfer & Support Services
Chemistry, Manufacturing and Controls
Contract Research Organization
Excipients & Specialty Ingredients
Others
Advanced Modalities
Company Overview
About
NerPharMa is an Italian CDMO (part of NMS Group, acquired by Benta in 2026) specializing in highly potent compounds with strong expertise in oncology. It operates two divisions: Drug Substance (API manufacturing in high containment glove-box suites, 50-250L reactors, 0.5-5 kg batches) and Drug Product (injectable solutions, suspensions, lyophilized products, and oral solid dosage forms including cytotoxic and cytostatic products).
Key Expertise
highly potent API manufacturing, oncology CDMO, high containment glove-box technology, cytotoxic drug product manufacturing, lyophilized injectables
Therapeutic Areas
Oncology
Immunology
Quick Facts
HQ:Italy
Capabilities & Services
Core Capabilities
- Small Molecule API
- Small Molecule Drug Product
- Oral Solid Dose
Dosage Forms
Oral Solid Dose
Sterile Injectable
Lyophilized (Freeze-Dried)
Containment Capabilities
Cytotoxic / ADC Handling
Production Scales
R&D / Pre-clinical
Lab Scale
Pilot Scale
Phase I Clinical Trials
Phase II
Clinical
Phase III Clinical Trials
Commercial Scale
Annual Capacity
Small Batch / R&D (< 100 kg/year)
Medium Clinical (100 - 1,000 kg/year)
Markets Served
Europe
Manufacturing Facilities
1 site worldwide
NerPharMa srl (NMS Group) - Italy Facility
Italy
Site Capabilities
3 capabilitiesBiologics Manufacturing
Monoclonal Antibodies
Vaccines
Certifications
NMPA (China)
National Medical Products Administration
FDA Registration
U.S. Food and Drug Administration
EMA GMP Certificate
European Medicines Agency
PMDA (Japan Pharmaceuticals and Medical Devices Agency)
Pharmaceuticals and Medical Devices Agency